# Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

> **NCT00417807** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Refractory Desmoplastic Small Round Cell Tumors

## Interventions

- **DRUG:** Imatinib mesilate

## Key facts

- **NCT ID:** NCT00417807
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2010-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417807, "Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00417807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*